神经药理学报››2016,Vol. 6››Issue (1): 35-40.DOI:10.3969/j.issn.2095-1396.2016.01.005
张美金,王莎莎,张钊,陈乃宏,胡金凤
出版日期:
2016-02-26发布日期:
2016-05-10通讯作者:
胡金凤,副研究员,硕士生导师;研究方向:神经精神药理学;E-mail:hujinfeng@imm.ac.cn作者简介:
张美金,硕士研究生;研究方向:神经精神药理学;E-mail:zhangmeijin@imm.ac.cn基金资助:
国家自然科学基金项目(No.81274122、No.81373997、No.81273629、No.81473376、No.U1402221、No.81573640),北京市自然科学基金项目(No.7131013),新药作用机制研究与药效评价北京市重点实验室资助项目(No.BZ0150)
ZHANG Mei-jin,WANG Sha-sha,ZHANG Zhao,CHEN Nai-hong,HU Jin-feng
Online:
2016-02-26Published:
2016-05-10Contact:
胡金凤,副研究员,硕士生导师;研究方向:神经精神药理学;E-mail:hujinfeng@imm.ac.cnAbout author:
张美金,硕士研究生;研究方向:神经精神药理学;E-mail:zhangmeijin@imm.ac.cnSupported by:
国家自然科学基金项目(No.81274122、No.81373997、No.81273629、No.81473376、No.U1402221、No.81573640),北京市自然科学基金项目(No.7131013),新药作用机制研究与药效评价北京市重点实验室资助项目(No.BZ0150)
摘要:核因子E2 相关因子2(nuclear factor erythroid-2-related factor 2,Nrf2)是细胞调节抗氧化应激反应的重要转录因子,其与抗氧化反应元件(anti-oxidative response element,ARE)结合,形成的Keap1-Nrf2-ARE 信号通路是机体抵抗内、外氧化应激的关键保护性通路。现有研究显示Keap1-Nrf2-ARE 信号通路对帕金森病患者具有重要的神经保护作用。该文对近年来Nrf2 在治疗帕金森病方面的作用及其机制,以及以Nrf2 为药物治疗靶点治疗帕金森病的最新研究成果进行总结。
中图分类号:
张美金,王莎莎,张钊,陈乃宏,胡金凤.核转录因子Nrf2 在帕金森病中的作用[J]. 神经药理学报, 2016, 6(1): 35-40.
ZHANG Mei-jin,WANG Sha-sha,ZHANG Zhao,CHEN Nai-hong,HU Jin-feng.Role of Nuclear Transcription Factor Nrf2 in Parkinson’s Disease[J]. Acta Neuropharmacologica, 2016, 6(1): 35-40.
[1] David T Dexter, Peter Jenner. Parkinson disease: from pathology to molecular disease mechanisms[J]Free Radical Biology & Medicine, 2013, 62: 132-144. [2] Denis Ottolini, Tito Cali, Alessandro Negro, et al. The Parkinson disease-related protein DJ-1 counteracts mitochondrial impairment induced by the tumour suppressor protein p53 by enhancing endoplasmic reticulum-mitochondria tethering[J].Human Molecular Genetics, 2013, 22(11): 2152-2168. [3] Hans-Hermann Hoepken, Suzana Gispert, Mekhman Azizov, et al. Parkinson patient fibroblasts show increased alpha-synuclein expression[J].Experimental Neurology, 2008, 212(2): 307-313. [4] Filio Billia, Ludger Hauck, Daniela Grothe, et al. Parkinson-susceptibility gene DJ-1/PARK7 protects the murine heart from oxidative damage in vivo[J].Proceedings National Academy Sciences USA, 2013, 110(15): 6085-6090. [5] Antonio Cuadrado, Paz Moreno-Murciano, Jose Pedraza-Chaverri. The transcription factor Nrf2 as a new therapeutic target in Parkinson's disease[J].Expert Opinion Therapeutic Targets, 2009, 13(3): 319-329. [6] Moi P, Chan K, Asunis I, et al. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region[J]. Proceedings National Academy Sciences USA, 1994, 91(21): 9926-9930. [7] Yu Xiang, Thomas Kensler. Nrf2 as a target for cancer chemoprevention[J]. Mutation Res, 2005, 591(1-2):93-102. [8] Lv E, Deng J, Yu Y, et al. Nrf2-ARE signals mediated the anti-oxidative action of electroacupuncture in an MPTP mouse model of Parkinson's disease[J]. Free Radical Res, 2015, 49(11): 1296-1307. [9] Gerasimos P Sykiotis, Dirk Bohmann. Stress-activated cap'n'collar transcription factors in aging and human disease[J]. Science Signaling, 2010, 3(112): re3. [10] Yaeko Takagi, Makoto Kobayashi, Li Li, et al. MafT, a new member of the small Maf protein family in zebrafish[J]. Biochemical Biophysical Research Communications, 2004, 320(1): 62-69. [11] Wang Bing, Liu Qing-qing, Shan Hong-yun, et al. Nrf2 inducer and cncC overexpression attenuates neurodegeneration due to alpha-synuclein in Drosophila[J]. Biochemistry Cell Biology, 2015, 93(4): 351-358. [12] Gui Ya-xing, Zhang Li-shan, Lv Wen, et al. NFE2L2 variations reduce antioxidant response in patients with Parkinson disease[J]. Oncotarget, 2016, 7(10): 10756-10764. [13] Marcelo R Vargas, Jeffrey A Johnson. The Nrf2-ARE cytoprotective pathway in astrocytes[J]. Expert Reviews Molecular Medicine, 2009, 11: e17. [14] Jamie Gonzalez, Nicolas Valls, Roberto Brito, et al. Essential hypertension and oxidative stress: New insights[J]. J World Cardiology, 2014, 6(6): 353-366. [15] Patricia M Chege, Gawain McColl. Caenorhabditis elegans: a model to investigate oxidative stress and metal dyshomeostasis in Parkinson's disease[J]. Frontiers Aging Neuroscience, 2014, 6: 89. [16] Justin Davis, Steven Moylan, Brian H Harvey, et al. Neuroprogression in schizophrenia: Pathways underpinning clinical staging and therapeutic corollaries[J]. J Australian New Zealand Psychiatry, 2014, 48(6): 512-529. [17] Helga E de Vries, Maarten Witte, David Hondius, et al. Nrf2-induced antioxidant protection: a promising target to counteract ROS-mediated damage in neurodegenerative disease?[J].Free Radical Biology & Medicine, 2008, 45(10): 1375-1383. [18] Gururaj Joshi, Jeffrey A Johnson. The Nrf2-ARE pathway: a valuable therapeutic target for the treatment of neurodegenerative diseases[J]. Recent Patents CNS Drug Discovery, 2012, 7(3):218-229. [19] Jong-Min Lee, Andy Y Shih, Timothy H Murphy, et al. NF-E2-related factor-2 mediates neuroprotection against mitochondrial complex I inhibitors and increased concentrations of intracellular calcium in primary cortical neurons[J]. J Biological Chemistry, 2003, 278(39): 37948-37956. [20] Izaskun Buendia, Patrycja Michalska, Elisa Navarro, et al. Nrf2-ARE pathway: An emerging target against oxidative stress and neuroinflammation in neurodegenerative diseases[J]. Pharmacology & Therapeutics, 2016, 157: 84-104. [21] Sankar Surendran, Srinivasagam Raja Sankar. Parkinson's disease: oxidative stress and therapeutic approaches[J]. Neurol Sci, 2010, 31(5): 531-540. [22] Chenere P Ramsey, Charles A Glass, Marshall B Montgomery, et al. Expression of Nrf2 in neurodegenerative diseases[J]. J Neuropathol Exp Neurol, 2007, 66(1): 75-85. [23] Ali Samii, John Nutt, Bruce R Ransom. Parkinson's disease[J]. Lancet, 2004, 363(9423): 1783-1793. [24] Suzanne Lesage, Alexis Brice. Parkinson's disease: from monogenic forms to genetic susceptibility factors[J]. Human Molecular Gen, 2009, 18(R1): R48-59. [25] John N Caviness, LihFen Lue, Charles H Adler, et al. Parkinson's disease dementia and potential therapeutic strategies[J]. CNS Neuroscience & Therapeutics, 2011, 17(1): 32-44. [26] Radhika Sampat, Sarah Young, Ami Rosen, et al. Potential mechanisms for low uric acid in Parkinson disease[J]. J Neural Transm, 2016, 123(4): 365-370. [27] Delinda A Johnson, Jeffrey A Johnson. Nrf2-a therapeutic target for the treatment of neurodegenerative diseases[J]. Free Radical Biology & Medicine, 2015, 88(Pt B): 253-267. [28] Brent J Ryan, Lara L Lourenco-Venda, Mark J Crabtree, et al. alpha-Synuclein and mitochondrial bioenergetics regulate tetrahydrobiopterin levels in a human dopaminergic model of Parkinson disease[J]. Free Radical Biology & Medicine, 2014, 67: 58-68. [29] Gan Li, Jeffrey A Johnson. Oxidative damage and the Nrf2-ARE pathway in neurodegenerative diseases[J]. Biochimica et Biophysica Acta, 2014, 1842(8): 1208-1218. [30] He Qing, Song Ning, Jia Feng-jv, et al. Role of alpha-synuclein aggregation and the nuclear factor E2-related factor 2/heme oxygenase-1 pathway in iron-induced neurotoxicity[J]. J Int Biochemistry & Cell Biology, 2013, 45(6): 1019-1030. [31] Li Gan, Marcelo R Vargas, Delinda A Johnson, et al. Astrocyte-specific overexpression of Nrf2 delays motor pathology and synuclein aggregation throughout the CNS in the alpha-synuclein mutant (A53T) mouse model[J]. J Neuroscience, 2012, 32(49): 17775-17787. [32] Lin Xiang-min, Travis J Cook, Cyrus P Zabetian, et al. DJ-1 isoforms in whole blood as potential biomarkers of Parkinson disease[J]. Scientific Reports, 2012, 2(50): 954. [33] Casey M Clements, Richard S McNally, Brian J Conti, et al. DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2[J]. Proceedings National Academy of Sciences USA, 2006, 103(41): 15091-15096. [34] Zhou Wen-bo, Curt R Freed. DJ-1 up-regulates glutathione synthesis during oxidative stress and inhibits A53T alpha-synuclein toxicity[J]. J Biological Chemistry, 2005, 280(52): 43150-43158. [35] Ana I Rojo, Nadia G Innamorato, Ana M Martin-Moreno, et al. Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease[J].Glia, 2010, 58(5): 588-598. [36] Rebekah J Jakel, Jessica A Townsend, Andrew D Kraft, et al. Nrf2-mediated protection against 6-hydroxydopamine[J]. Brain Res, 2007, 1144: 192-201. [37] Agnieszka Jazwa, Ana I Rojo, Nadia G Innamorato, et al. Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism[J].Antioxidants & Redox Signaling, 2011, 14(12): 2347-2360. [38] Wruck C J, Claussen M, Fuhrmann G, et al. Luteolin protects rat PC12 and C6 cells against MPP+ induced toxicity via an ERK dependent Keap1-Nrf2-ARE pathway[J]. J Neural Transm Suppl, 2007, (72): 57-67. [39] Zhao Chun-yang, Wang Xiao-liang, Peng Ying. [Role of Nrf2 in neurodegenerative diseases and recent progress of its activators][J]. Acta Pharmaceutica Sinica, 2015, 50(4): 375-384. [40] Susanne Petri, Sonja Korner, Mahmoud Kiaei. Nrf2/ARE signaling pathway: key mediator in oxidative stress and potential therapeutic target in ALS[J].Neurology Res Int, 2012, 2012: 878030. [41] Tracy P Williamson, Delinda A Johnson, Jeffrey A Johnson. Activation of the Nrf2-ARE pathway by siRNA knockdown of Keap1 reduces oxidative stress and provides partial protection from MPTP-mediated neurotoxicity[J].Neurotoxicology, 2012, 33(3): 272-279. [42] Chen Pei-chun, Marcelo R Vargas, Amar K Pani, et al. Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyte[J].Proceed National Academy of Sciences USA, 2009, 106(8): 2933-2938. [43] Hyman M Schipper. Heme oxygenase expression in human central nervous system disorders[J].Free Radical Biology Med, 2004, 37(12):1995-2011. [44] Andy Y Shih, Delinda A Johnson, Gloria Wong, et al. Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress[J]. J Neuroscience, 2003, 23(8):3394-3406. [45] Xiao Hai-bing, Lv Feng, Xu Wu-ping, et al. Deprenyl prevents MPP(+)-induced oxidative damage in PC12 cells by the upregulation of Nrf2-mediated NQO1 expression through the activation of PI3K/Akt and Erk[J].Toxicology, 2011, 290(2-3): 286-294. |
[1] | 杨杰,刘富甲,田子夏,王乐乐,谢欣梅,庞晓斌.脉络宁对MCAO 大鼠的神经保护作用及其抗氧化机制研究[J]. 神经药理学报, 2017, 7(4): 1-7. |
[2] | 杜云广,曹欣欣,王晓茹,王书华.牡荆苷对脑缺血再灌注大鼠脑损伤保护作用及其机制研究[J]. 神经药理学报, 2017, 7(1): 10-23. |
[3] | 颜娟,郑茂东,崔玉环,魏玉磊,田青青,张丹参.大黄酚脂质体对脑缺血再灌注损伤小鼠动态抗氧化作用研究[J]. 神经药理学报, 2016, 6(1): 9-17. |
[4] | 刘军举,付冬君,牛进波,张旗,张雁冰.2’- 溴-2- 羟基-4,6,4’,5’- 四甲氧基查尔酮抑制SK-N-SH 细胞增殖的作用研究[J]. 神经药理学报, 2016, 6(1): 18-24. |
[5] | 李黎,张海林.CCL2/CCR2 参与神经病理性疼痛的多靶点作用机制[J]. 神经药理学报, 2016, 6(1): 49-57. |
[6] | 宋晓敏, 庄忠宝, 张海威, 张 力.性别对两种溃疡性结肠炎模型的影响[J]. 神经药理学报, 2015, 5(6): 11-20. |
[7] | 王克柱,孙军花, 徐攀, 陈红英, 代志, 王晓英, 刘新民.硝酸甘油诱导的偏头痛大鼠自主活动的变化[J]. 神经药理学报, 2015, 5(3): 6-11. |
[8] | 张丹参,王倩,田慧,薛贵平,张力.大黄栓制剂对两种溃疡性结肠炎模型小鼠的作用研究[J]. 神经药理学报, 2015, 5(1): 19-37. |
[9] | 岳旺,张继国,杨杰,周涛,张丹参,孙芳,徐权汉,张述智,李晓玲.斑马鱼—一种新型电惊厥动物模型[J]. 神经药理学报, 2014, 4(6): 17-20. |
[10] | 楚世峰,张均田.一种新型的抗老年痴呆剂:左旋黄皮酰胺的化学、生物学活性和作用机制研究[J]. 神经药理学报, 2014, 4(6): 33-43. |
[11] | 武海霞,吴志刚,刘红彬,沈丽霞.Morris水迷宫实验在空间学习记忆研究中的应用[J]. 神经药理学报, 2014, 4(5): 30-35. |
[12] | 刘旻, 郭海彪, 李楚源, 王德勤, 徐江平, 覃仁安.复方丹参片早期干预对APP/PS1转基因小鼠的学习记忆影响[J]. 神经药理学报, 2014, 4(5): 1-7. |
[13] | 赵薇, 李方江, 王树.大黄酚对小鼠脑缺血再灌注引起肝损伤的保护作用[J]. 神经药理学报, 2014, 4(4): 1-9. |
[14] | 赵楠, 张黎明, 李云峰.小鼠条件性电击社交恐惧行为模型的建立与评价[J]. 神经药理学报, 2014, 4(4): 15-19. |
[15] | 曹欣欣,王书华.金莲花药理活性及临床应用研究进展[J]. 神经药理学报, 2014, 4(4): 59-64. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||